Strs Ohio Purchases 38,300 Shares of Exact Sciences Corporation (EXAS)
Strs Ohio raised its position in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 181.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 59,400 shares of the medical research company’s stock after buying an additional 38,300 shares during the quarter. Strs Ohio’s holdings in Exact Sciences Corporation were worth $2,798,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. State of Wisconsin Investment Board purchased a new position in Exact Sciences Corporation during the second quarter valued at $3,006,000. Victory Capital Management Inc. purchased a new position in Exact Sciences Corporation during the second quarter valued at $29,450,000. Eagle Asset Management Inc. lifted its position in Exact Sciences Corporation by 19.6% during the second quarter. Eagle Asset Management Inc. now owns 1,857,185 shares of the medical research company’s stock valued at $65,688,000 after buying an additional 304,598 shares during the period. Federated Investors Inc. PA lifted its position in Exact Sciences Corporation by 53.3% during the second quarter. Federated Investors Inc. PA now owns 34,553 shares of the medical research company’s stock valued at $1,222,000 after buying an additional 12,018 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in Exact Sciences Corporation during the first quarter valued at $8,298,000. 85.12% of the stock is owned by institutional investors and hedge funds.
In related news, Director Thomas D. Carey acquired 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The stock was purchased at an average cost of $37.71 per share, for a total transaction of $94,275.00. Following the purchase, the director now directly owns 60,858 shares of the company’s stock, valued at approximately $2,294,955.18. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Graham Peter Lidgard sold 81,025 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total value of $3,821,139.00. Following the sale, the insider now owns 366,519 shares of the company’s stock, valued at $17,285,036.04. The disclosure for this sale can be found here. Insiders have sold a total of 231,598 shares of company stock valued at $10,182,030 over the last 90 days. 4.00% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Strs Ohio Purchases 38,300 Shares of Exact Sciences Corporation (EXAS)” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://theolympiareport.com/2017/11/01/strs-ohio-purchases-38300-shares-of-exact-sciences-corporation-exas.html.
Several equities analysts have commented on EXAS shares. Leerink Swann set a $45.00 price objective on Exact Sciences Corporation and gave the company a “buy” rating in a research report on Thursday, August 24th. Robert W. Baird reissued a “buy” rating and set a $49.00 price objective on shares of Exact Sciences Corporation in a research report on Friday, October 6th. Bank of America Corporation set a $56.00 price objective on Exact Sciences Corporation and gave the company a “buy” rating in a research report on Thursday, October 19th. Zacks Investment Research raised Exact Sciences Corporation from a “hold” rating to a “buy” rating and set a $51.00 price objective for the company in a research report on Tuesday, September 26th. Finally, Canaccord Genuity reissued a “buy” rating and set a $60.00 price objective (up previously from $45.00) on shares of Exact Sciences Corporation in a research report on Tuesday, October 3rd. Six investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $49.71.
Exact Sciences Corporation (NASDAQ:EXAS) opened at 54.99 on Wednesday. The stock’s 50 day moving average price is $47.06 and its 200 day moving average price is $38.47. Exact Sciences Corporation has a one year low of $13.05 and a one year high of $57.95. The company’s market capitalization is $6.55 billion.
Exact Sciences Corporation (NASDAQ:EXAS) last issued its quarterly earnings data on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.07. The firm had revenue of $72.60 million during the quarter, compared to analysts’ expectations of $65.03 million. Exact Sciences Corporation had a negative return on equity of 32.85% and a negative net margin of 60.71%. The firm’s quarterly revenue was up 158.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.36) EPS. Equities analysts anticipate that Exact Sciences Corporation will post ($1.17) EPS for the current fiscal year.
Exact Sciences Corporation Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.